2020
Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach
Castry M, Cousien A, Supervie V, Velter A, Ghosn J, Paltiel AD, Yazdanpanah Y, Deuffic-Burban S. Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach. Gut 2020, 70: 1561-1569. PMID: 33109688, DOI: 10.1136/gutjnl-2020-321744.Peer-Reviewed Original ResearchConceptsHCV incidenceRisk reduction strategiesHCV epidemicEarly HCV diagnosisHCV natural historyHCV risk behaviorsDrug-related behaviorsEpidemic of HCVHCV cascadeHCV prevalenceDynamic compartmental modelHCV eliminationHCV transmissionHCV diagnosisFrequent screeningWHO targetHIVRisk behaviorsNatural historyMSMCurrent French practicesIncidenceHCVImpact of testEpidemicNovel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population
Reddy KP, Bulteel AJB, Levy DE, Torola P, Hyle EP, Hou T, Osher B, Yu L, Shebl FM, Paltiel AD, Freedberg KA, Weinstein MC, Rigotti NA, Walensky RP. Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. BMJ Open 2020, 10: e032579. PMID: 32404384, PMCID: PMC7228509, DOI: 10.1136/bmjopen-2019-032579.Peer-Reviewed Original ResearchConceptsNational Health Interview SurveyCessation ratesQuit attemptsTobacco useMortality riskSmoking relapseSurveillance Modeling Network (CISNET) modelsNational Death IndexHealth Interview SurveyCigarette smoking behaviorNicotine product useExternal validationCumulative mortality curvesTobacco control policiesTobacco use behaviorsCurrent smokersDeath IndexSmoking prevalenceSustained abstinenceUS womenRelapseSmoking behaviorWomen/menUS populationNatural history
2017
The Inclusion Body Myositis Registry at Yale: A growing information database and practical tool for researchers, clinicians, and patients
Cotzomi E, Petschke K, O'Connor K, Paltiel A. The Inclusion Body Myositis Registry at Yale: A growing information database and practical tool for researchers, clinicians, and patients. Muscle & Nerve 2017 DOI: 10.1002/mus.25774.Peer-Reviewed Original Research
2015
Demographic and clinical features of inclusion body myositis in north America
Paltiel AD, Ingvarsson E, Lee DK, Leff RL, Nowak RJ, Petschke KD, Richards-Shubik S, Zhou A, Shubik M, O'Connor KC. Demographic and clinical features of inclusion body myositis in north America. Muscle & Nerve 2015, 52: 527-533. PMID: 25557419, PMCID: PMC4869122, DOI: 10.1002/mus.24562.Peer-Reviewed Original ResearchConceptsInclusion body myositisBody myositisDaily livingComposite functional indexLarger patient populationWeakness of armsDisease durationClinical featuresInitial diagnosisMean agePatient populationFemale ratioClinical managementClinical trialsOutcome measuresFirst symptomsFunctional indexEarly symptomsNatural historyMean timeSelf-report surveyMyositisPatientsSymptomsDiagnosis
2001
Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model
Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2001, 108: 39-in4. PMID: 11447380, DOI: 10.1067/mai.2001.116289.Peer-Reviewed Original ResearchConceptsSymptom-free daysCorticosteroid therapyAcute exacerbationModerate asthmaHealth-related qualityPopulation of patientsCost-effectiveness findingsHealth care costsCost-effectiveness analysisTotal health costsAdult asthmaObservational cohortRandomized trialsPatient preferencesPatient surveyClinical impactCorticosteroidsSide effectsCare costsDrug efficacyNatural historyAsthmaIncremental costTherapyMild
1998
The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients
Paltiel A, Freedberg K. The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients. Interfaces 1998, 28: 34-51. DOI: 10.1287/inte.28.3.34.Peer-Reviewed Original ResearchIncidence of infectionLate-stage HIV diseaseToxicity of therapyNational cohort studyProgression of illnessCost-effectiveness resultsPrice of therapyCMV prophylaxisCytomegalovirus diseaseCytomegalovirus infectionHIV diseaseCohort studyPatients' qualityAIDS patientsClinical trialsNatural historyInfectionProphylaxisTherapyIncidenceDiseaseCompartmental modelPatientsIllnessProgression